ExploreWatchlistsPricing
  1. JP-listed companies
  2. Shionogi & Co.,Ltd.
  3. Financials
  4. Revenue growth (%)

Shionogi & Co.,Ltd. (4507)

Market cap
¥2.86T
P/E ratio
14.6x
Develops, manufactures and sells prescription pharmaceuticals globally, specializing in infectious diseases and central nervous system disorders.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 20256.9-276.86%
Mar 31, 2024-3.9-114.24%
Mar 31, 202327.3+113.94%
Mar 31, 202212.8-213.21%
Mar 31, 2021-11.3+42.60%
Mar 31, 2020-7.9-243.04%
Mar 31, 20195.5+225.29%
Mar 31, 20181.7-81.78%
Mar 31, 20179.3-28.94%
Mar 31, 201613.1-341.80%
Mar 31, 2015-5.4-325.31%
Mar 31, 20142.4-58.80%
Mar 31, 20135.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat